Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.

[1]  F. Tavassoli,et al.  Invasive micropapillary carcinoma of the breast. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  Mahul B. Amin,et al.  Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder Histologic Pattern Resembling Ovarian Papillary Serous Carcinoma , 1994, The American journal of surgical pathology.

[3]  M. Sherman,et al.  Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. , 1996, The American journal of surgical pathology.

[4]  A. Marchetti,et al.  BRONCHIOLOALVEOLAR LUNG CARCINOMAS: K‐ras MUTATIONS ARE CONSTANT EVENTS IN THE MUCINOUS SUBTYPE , 1996, The Journal of pathology.

[5]  L. Ylagan,et al.  Micropapillary Variant of Transitional Cell Carcinoma of the Urinary Bladder , 2001, Acta Cytologica.

[6]  J. Minna,et al.  Focus on lung cancer. , 2002, Cancer cell.

[7]  Syed Z. Ali,et al.  Micropapillary serous carcinoma of the ovary , 2002, Cancer.

[8]  Jungsil Ro,et al.  Micropapillary Component in Lung Adenocarcinoma: A Distinctive Histologic Feature With Possible Prognostic Significance , 2002, The American journal of surgical pathology.

[9]  三好 立,et al.  Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis , 2003 .

[10]  C. Chantranuwat.  Metastatic potentiality of micropapillary and conventional histological patterns: a comparative study of 82 pulmonary adenocarcinomas. , 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[11]  D. Visscher,et al.  Invasive Micropapillary Salivary Duct Carcinoma: A Distinct Histologic Variant With Biologic Significance , 2004, The American journal of surgical pathology.

[12]  H. Iwasaki,et al.  Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours) , 2005, Histopathology.

[13]  M. Jiménez-Ayala.  Micropapillary Carcinoma and Mucinous Carcinoma with a Micropapillary Pattern , 2007, Acta Cytologica.

[14]  M. Hollingsworth,et al.  A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis , 2007, Modern Pathology.

[15]  N. Moreno,et al.  Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. , 2008, Human pathology.

[16]  K. Mimori,et al.  Cancer stem cells and chemoradiation resistance , 2008, Cancer science.

[17]  Jian-ming Li,et al.  Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. , 2008, Journal of proteome research.

[18]  W. Gerald,et al.  Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.

[19]  M. Nikiforova,et al.  Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. , 2009, American journal of clinical pathology.

[20]  G. Giaccone,et al.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2010, Journal of oncology practice.

[21]  H. Shim,et al.  Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. , 2011, Archives of pathology & laboratory medicine.

[22]  H. Lee,et al.  High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[24]  M. L. R. D. Christenson,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2012 .

[25]  K. Jordan,et al.  Incidence of prostate, breast, lung and colorectal cancer following new consultation for musculoskeletal pain: A cohort study among UK primary care patients , 2013, International journal of cancer.

[26]  Yi-long Wu,et al.  Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. , 2013, Lung cancer.

[27]  A. Yoshizawa,et al.  Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. , 2013, Lung cancer.

[28]  J. Suh.  Current readings: pathology, prognosis, and lung cancer. , 2013, Seminars in thoracic and cardiovascular surgery.

[29]  B. Parasuraman,et al.  EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital , 2013, PloS one.

[30]  P. Littlefield,et al.  EGFR lung cancer mutants get specialized , 2013, Proceedings of the National Academy of Sciences.

[31]  P. Souquet,et al.  Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes , 2013, Lung.

[32]  V. Gebski,et al.  Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. , 2013, Journal of the National Cancer Institute.

[33]  D. Jain.  Low papillary structures in lepidic lung adenocarcinoma: any relationship with micropapillary lung adenocarcinoma? , 2013, Human pathology.

[34]  Prasad S Adusumilli,et al.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. , 2013, Journal of the National Cancer Institute.

[35]  Haiquan Chen,et al.  PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup , 2014, PloS one.

[36]  F. Feuerhake,et al.  High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. , 2014, Clinical lung cancer.